Fighting cancer with rejection-resistant, ‘off-the-shelf’ therapeutic T cells

Personalized cancer treatments are no longer just options of the future. In the past few years, researchers have made significant progress in ‘teaching’ the body’s immune T cells to recognize and kill specific cancer cells, and human clinical trials have shown that this approach can successfully eliminate tumors.

Cancer patients today can be a part of the following clinical scenario: a patient comes to the hospital where physicians and scientists analyze his or her tumor to identify cancer-specific markers that would serve as targets for the novel therapy. Blood is drawn from the patient and sent to Baylor College of Medicine’s Center for Cell and Gene Therapy where the immune T cells are transformed into cells with a mission to identify and kill cells with the tumor-specific tags. The final cells are infused back into the patient to complete their job.

“At the Center, we genetically engineer the patient’s T cells to arm them with the tools they need to identify the patient’s tumor-specific markers and eliminate the cancer,” said Dr. Maksim Mamonkin, assistant professor of pathology & immunology and member of the Center for Cell and Gene Therapy at Baylor.

Although this treatment can effectively eliminate tumors, the ‘training’ of the T cells is complex and expensive. “Sometimes, the trained T cells are not highly potent because the patient already received a number of treatments that weakened the immune cells we work with,” Mamonkin said.

In addition, the process to manufacture the therapeutic T cells is time consuming. “Sometimes it takes weeks to get the T cells ready, and in this time the patient may take a turn for the worse,” Mamonkin said.

The next step: off-the-shelf therapies

“Now that we know that this type of cell immunotherapy has a lot of promise, the next step is to streamline it, make it more accessible and make sure that the resulting T cells have the highest potency,” said Mamonkin, who also is a member of the Dan L Duncan Comprehensive Cancer Center.

Researchers are developing ready-to-use, off-the-shelf therapeutic T cells. These are genetically engineered T cells that are manufactured from normal, healthy donors. The cells are expanded and well characterized, and have shown to be effective at killing cancer cells. The cells are cryo-preserved – stored frozen in liquid nitrogen – until it’s time to use them.

In this scenario, a cancer patient comes to the hospital and the tumor markers are identified. Then, with the identity of the tumor-specific tags in hand, the physician goes to a room filled with large below-zero freezers searching for the one that holds little containers with healthy immune T cells that have been genetically engineered to recognize and destroy cells with the patient’s cancer-specific markers. These ‘off-the-shelf,’ ready-made cells are thawed, prepared and infused into the patient several days later.

Dealing with rejection

One of the limitations of the off-the-shelf approach emerges when the therapeutic T cells enter the patient’s body. The patient’s own immune system recognizes the cells as foreign, such as it happens with organ transplants, and may reject the therapeutic cells.

“This is a major problem because rejection not only would reduce the duration of the T cells activity against the tumor, but also would preclude giving subsequent doses of cells. The immune system would reject subsequent doses of the cells right way,” said first author, Feiyan Mo, graduate student in Mamonkin’s lab. “To solve this problem we thought that the best defense was a good offense.”

The researchers gave the therapeutic T cells a tool that would enable them to fight back the attack of the patient’s immune cells against them. They genetically engineered the therapeutic T cells to express a receptor called alloimmune defense receptor, or ADR. ADR recognizes a specific molecule, called 4-1BB, that is only expressed on the patient’s activated T cells and natural killer (NK) cells that would attack them. 4-1BB is not expressed on resting T and NK cells that do not turn against the therapeutic T cells.

The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.